radium Ra 223 dichloride

Trials studying radium Ra 223 dichloride

• phase4RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)active not recruitingn=654
• phase3A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastasescompletedn=921
• —Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancerrecruitingn=48
• —Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancercompletedn=1,472
• phase1A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bonescompletedn=46
• —Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastasescompletedn=334
• phase2Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bonecompletedn=20
• phase1Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)completedn=14